Recruiting Clinical Trials

Displaying 31 - 40 of 227 result(s)
Study Title Condition Phase Location
Phase III Study for Evaluation of the Diagnostic Performance of [18F]CTT1057 PET Imaging in Patients With Prostate Cancer With Rising PSA Levels [Biochemical Recurrence (BCR)] Prostatic Neoplasms, Prostate Cancer, Recurrence Phase 3
  • Country: 
    France
  • Country: 
    Spain
  • Country: 
    Switzerland
Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France: a National, Multicenter, Prospective, Non-interventional Study Breast Cancer Not Given
  • Country: 
    France
A Prospective, Open Label, Multicenter, Single Arm, Phase 2 Study of 177Lu-PSMA-617 in the Treatment of Participants With Progressive PSMA- Positive Metastatic Castration-resistant Prostate Cancer (mCRPC) in Japan Prostate Cancer Phase 2
  • Country: 
    Japan
A Phase II, Double-blind, Randomized, Multiple Dose, Cross Over, Three-treatment, Three-period, Six Sequence Placebo Controlled Trial to Evaluate Efficacy, Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety and Tolerability of Glycopyrronium (Br ... Asthma Phase 2
  • Country: 
    Bulgaria
  • Country: 
    Hungary
  • Country: 
    Poland
  • Country: 
A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Who Had an Insufficient Response or Relapsed After First Line Steroid Treatment (VAYHIT2) Primary Immune Thrombocytopenia Phase 3
  • Country: 
    Singapore
A Phase Ib, Multicenter, Open-label Platform Study of Select Drug Combinations in Adult Patients With Lower Risk (Very Low, Low, or Intermediate Risk) Myelodysplastic Syndrome Myelodysplastic Syndromes Phase 1
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    China
  • Country: 
An Open-label, Multi-center Rollover Protocol for Continued Characterization of Safety and Tolerability for Subjects Who Have Participated in a Novartis-sponsored Spartalizumab Study as Single Agent or in Combination With Other Study Treatments Advanced Solid Tumors Phase 1
  • Country: 
    United States
  • Country: 
    Belgium
  • Country: 
    Canada
  • Country: 
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Prostatic Neoplasms Phase 3
  • Country: 
    United States
  • Country: 
    Austria
  • Country: 
    Belgium
  • Country: 
A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide and Tislelizumab in Induction and With Tislelizumab in M ... Extensive Stage Small Cell Lung Cancer Phase 1
  • Country: 
    France
  • Country: 
    Spain
A Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies Non-small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal SCC, Gastrointestinal Stromal Tumors, Colorectal Cancer Phase 1
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Belgium
  • Country: